CONCISE REPORT

Elimination of Acute Myelogenous Leukemic Cells From Marrow and Tumor Suspensions in the Rat With 4-Hydroperoxycyclophosphamide

By Saul J. Sharkis, George W. Santos, and Michael Colvin

Cell suspensions of normal rat marrow mixed with rat acute myelogenous leukemic cells were prepared and incubated in vitro with graded doses of 4-hydroperoxycyclophosphamide (4HC). The cell suspensions were injected into rats prepared with a lethal dose of total body irradiation. Animals injected with these cells survived fatal irradiation induced aplasia. In a dose related manner 4HC was able to “purge” tumor cells from the cell mixtures. Thus, animals given cell suspensions incubated with the lower doses of 4HC showed prolonged survival before death from leukemia and animals given cell suspensions incubated with higher doses of 4HC survived lethal irradiation without the subsequent appearance of leukemia. These studies clearly establish that tumor cells may be eliminated from normal marrow suspensions without completely destroying the pluripotent stem cells.

ALLOGENEIC bone marrow transplantation has become the therapy of choice in severe aplastic anemia and in certain cases of severe combined immunodeficiency. The role of this procedure in the treatment of malignancy in general and in acute leukemia in particular remains to be firmly established. Recent data, however, suggest that the therapeutic results in acute leukemia may be markedly improved if patients are entered into a transplantation protocol when they are in remission. Allogeneic marrow transplantation nevertheless remains limited in its therapeutic potential because of graft-versus-host disease, profound posttransplantation immunodeficiency, and interstitial pneumonitis.

Bone marrow transplantation in hematologic malignancies has shown considerable promise when identical twin donors were employed. These transplants are not complicated by graft-versus-host disease and, in addition, have a marked reduction of interstitial pneumonitis and duration of posttransplantation immunodeficiency.

Unfortunately, identical twin donors are rare, but the therapeutic results obtained with these patients have encouraged a number of transplant centers to consider more imaginative uses of autologous remission marrow for transplantation. Remission marrow suspensions undoubtedly contain undetectable tumor cells. Clearly, if the use of such marrow is to be optimized, remaining tumor cells must be eliminated. Evidence that rodent marrow may be “purged” of tumor cells by antibody without destroying the pluripotent hematopoietic stem cells has been presented.

Previously, we reported our experience with syngeneic marrow transplantation in a rat model of acute myelogenous leukemia (AML). In that report we indicated that this tumor was remarkably sensitive to cyclophosphamide (Cy).

The purpose of this article is to report our initial trials in “purging” AML from rat marrow without destroying hematopoietic stem cells by short incubation with the Cy analogue, 4-hydroperoxycyclophosphamide (4HC).

MATERIALS AND METHODS

Animals

Female (Lewis × BN)F1, (LBNF1) (Ag-B1,3) rats, 10–12 wk of age, were obtained from Microbiological Associates (BETHESDA, Md.). The animals were housed in polycarbonate cages, two to a cage. They were provided with tap water and Purina chow ad libitum.

Drugs and Total Body Irradiation (TBI)

4-Hydroperoxycyclophosphamide (4HC) is an analogue of cyclophosphamide that spontaneously decomposes in aqueous solution to generate either the primary metabolites of cyclophosphamide or compounds with similar chemical and biologic properties to these metabolites. Studies examining the cytotoxic and crosslinking activity of this compound demonstrate that it shows essentially equal activity when compared with the metabolites generated by the microosomal metabolism of Cy. Therefore, the compound was utilized for in vitro studies to test the cytoreductive activity of Cy. The 4HC used in the present experiments was synthesized by one of the authors (M. Colvin). The 4HC was dissolved in RPMI 1640 in the appropriate concentrations.

Cyclophosphamide as compared to several other agents, appears to have less stem cell toxicity. Furthermore, the rat AML tumor that was used in these studies was previously shown to be sensitive to Cy. For these reasons, 4HC seemed to be an appropriate agent to employ in experiments designed to “purge” AML tumor cells from normal marrow.

From the Oncology Center, Johns Hopkins University, Baltimore, Md.

Supported in part by USPHS Research Grants CAO-06973 and CA-15396 from the National Cancer Institute, National Institutes of Health, Bethesda, Md.

Submitted September 21, 1979; accepted November 1, 1979.

Address reprint requests to G.W. Santos, Bone Marrow Transplant Unit, Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Md. 21205.

© 1980 by Grune & Stratton, Inc.

0006-4971/80/5503-0026$01.00/0
Incubation Procedure

Petri dishes containing cold RPMI 1640. Clumps of cells were minced, and gently teased in RPMI 1640 solution, cell counts were made, and viability (90%–95%) was estimated with trypan blue, as described previously.6

Preparation of Cell Inocula

Marrow from the femur, tibia, and humerus was collected in cold RPMI 1640. Clumps of cells were minced, and gently teased in RPMI 1640. Clumps of cells were gently dispersed with the aid of a small syringe. Cell suspensions were counted and adjusted to the proper concentration as noted above. Viability as judged by trypan blue exclusion was 85%–95%. Cells were injected i.v. into rats in a constant 1-ml volume containing 106 cells.

Incubation Procedure

Marrow, tumor, or mixtures of marrow and tumor were incubated with appropriate concentrations of 4HC in RPMI 1640 at 37°C for 30 min and then directly (without centrifugation and washing) injected i.v. into recipients. Viability was not changed by the incubation procedure.

RESULTS

In preliminary studies, AML cells and normal LBNF1 marrow cells were separately incubated with 4HC to clear a mixture of normal marrow and tumor cells of AML cells in a dose-dependent manner that did not affect the ability of the cell suspensions to prevent the otherwise lethal effects of 1000 rad of TBI. The three animals that died of aplasia and the one that died of leukemia in the last three experimental groups in Table 1 appear to be exceptions that do not invalidate the above conclusions.

DISCUSSION

The use of autologous bone marrow transplantation is attractive, since it allows very intensive cytoreductive therapy to be applied to a greater number of patients with malignancy than would ordinarily be permitted. The use of autologous marrow also has the same potential advantages of syngeneic marrow in that many of the problems associated with allogeneic transplantation (e.g., GVHD) can be avoided. The same potential advantages of syngeneic marrow in that many of the problems associated with allogeneic transplantation (e.g., GVHD) can be avoided. The use of autologous bone marrow transplantation is attractive, since it allows very intensive cytoreductive therapy to be applied to a greater number of patients with malignancy than would ordinarily be permitted. The use of autologous marrow also has the same potential advantages of syngeneic marrow in that many of the problems associated with allogeneic transplantation (e.g., GVHD) can be avoided. The major disadvantage in using autologous marrow is the possible contamination of the marrow by tumor cells.

Tumor might be eliminated from marrow suspensions by physical methods, such as cell fractionation,7 or by pharmacologic means. Depending on the type of tumor to be cleared, the most
agents may show considerable promise in eliminating not only tumor cells for autologous marrow transplantation but also cells capable of initiating GVHD in allogeneic marrow transplantation.

The data reported here indicate that the incubation of marrow–tumor mixtures with 4HC may effectively eliminate tumor cells contaminating marrow suspensions without destroying the ability of the cell suspensions to reverse the lethal effects of high doses of TBI. Previously, Shand\textsuperscript{17} had shown that the incubation of parental spleen cells with 100 $\mu$g/ml of microsomal-activated Cy was able to abolish GVHD in mice without destroying hematopoietic stem cells. Thus, the data of Shand\textsuperscript{17} as well as the present report indicate that the incubation of marrow with chemotherapeutic agents may show considerable promise in eliminating not only tumor cells for autologous marrow transplantation but also cells capable of initiating GVHD in allogeneic marrow transplantation.

REFERENCES

Elimination of acute myelogenous leukemic cells from marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide

SJ Sharkis, GW Santos and M Colvin

Updated information and services can be found at: http://www.bloodjournal.org/content/55/3/521.full.html

Articles on similar topics can be found in the following Blood collections.